Navigation Links
Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
Date:5/12/2008

ible for the development

of the Staccato Electric Multiple Dose device, and the Company has the

exclusive right to manufacture the product for clinical development

and commercial supply.

-- AZ-007 (Staccato zaleplon). Alexza is developing AZ-007 for the

treatment of insomnia in patients who have difficulty falling asleep,

including patients who awake in the middle of the night and have

difficulty falling back asleep. In March 2008, Alexza completed

enrollment in a Phase 1 clinical trial of 40 healthy volunteers at a

single U.S. clinical center. The purpose of this trial was to assess

the safety, tolerability and pharmacokinetic parameters of a single

dose of AZ-007. Using a double-blind, randomized, dose-escalation

trial design, 4 doses of AZ-007 (ranging from 0.5 to 4.0 mg) were

compared to placebo.

In April 2008, Alexza announced positive initial results from the Phase 1 study. AZ-007 delivered an IV-like pharmacokinetic profile with a median time to peak venous concentration (Tmax) of 1.6 minutes. Zaleplon exposure was dose proportional across the 4 doses studied, as calculated by power analysis. Pharmacodynamics, measured as sedation self-assessed on a 100 mm visual-analog scale, showed onset of effect as early as 2 minutes after dosing with AZ-007. There were no serious adverse events. The most frequently reported adverse events in subjects receiving AZ-007 were dizziness and somnolence. These data indicate a rapid onset of effect, apparently directly related to the IV-like pharmacokinetics, and showed that AZ-007 was generally safe and well tolerated in this population of healthy volunteers.

Conference Call Information

Alexza will host a conference call today at 4:30 p.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to al
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
2. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
3. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
6. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
7. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
8. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
9. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
10. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
11. MGT Capital Investments Reports First Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- BioNano Genomics, Inc., the leader in genome mapping, announced ... commercial officer. Salyer has more than 20 years of ... sciences. At BioNano, Salyer will oversee the commercialization of ... assemble a comprehensive view of complex genomes to help ... located in the United States , ...
(Date:3/26/2015)... 26, 2015 "In America," the popular news ... States that is hosted by legendary film actor James Earl ... botany in an upcoming segment. , Botany is commonly ... it is actually quite a bit more complicated than that. ... types of living organisms, from the smallest bacteria known to ...
(Date:3/25/2015)... March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... a result of recent discussions with certain shareholders representing ... the Company, after dealing with certain matters including the ... of shareholders on March 26, 2015 (the "Meeting") it ... of directors will take place when the Meeting reconvenes. ...
(Date:3/25/2015)... , March 25, 2015 Accelovance, a therapeutically ... finalist for "Best Contract Research Organization" at the upcoming ... Vaccine Congress. This is the eighth ... for the award, winning for "Best Contract Research Organization" ... Recommended" distinction in 2013. "We,re excited to ...
Breaking Biology Technology:BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2
... Genomatica announced today that William ... time as executive chairman and chief business development officer. ... producers, users, feedstock suppliers, brands and retailers.   ... $500 million in partnerships Bill brings ...
... Genetic Risk Factor for the Most Common Form of... -- REYKJAVIK, Iceland, September 13, 2010 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... MOUNTAIN VIEW, Calif., Sept. 10 VIVUS, Inc. (Nasdaq: ... will present an overview of the company at four ... presentation schedule is as follows:Bank of America Merrill Lynch ... officerSeptember 16, 2010 at 2:30 p.m. BST Bank of ...
Cached Biology Technology:Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 2Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 3Bill Baum Joins Genomatica as it Ramps for Commercial Rollout 4deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 2deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 3deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 4deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 5deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 6deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 7deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma 8VIVUS to Present at Four Upcoming Investor Conferences 2
(Date:3/24/2015)... 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands by the following Segments: Face Biometrics, and ... Canada , Japan , ... Middle East & Africa , and ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... March 23, 2015   HOYOS Labs , a ... today announced that the Company will demonstrate multiple biometrics-based ... and consumers at Connect:ID on March 23 through 25, ... Labs will highlight the IEEE Biometric Open Protocol Standard; ... and enterprise access control system. BOPS was invented by ...
Breaking Biology News(10 mins):Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... SAN FRANCISCO, FEB. 10, 2011 -- Research presented today ... Medicine (SMFM) -- The Pregnancy Meeting has found that three ... part for the success of progesterone treatments in the prevention ... role in triggering normal labor. The proteins ...
... that we know everything about how the flea jumps, ... store the energy needed to catapult themselves into the ... in the intervening years debate raged about exactly how ... came up with competing hypotheses, but neither had access ...
... groups of lowly marine worms are related to complex species ... research. Previously thought to be an evolutionary link between simple ... - the worms, surprising promotion implies that they have not ... the marine worms Xenoturbella and Acoelomorpha ...
Cached Biology News:New research helps explain how progesterone prevents preterm birth 244-year-old mystery of how fleas jump resolved 244-year-old mystery of how fleas jump resolved 3Simple marine worms distantly related to humans 2
... Serum-free adapted Sf9 derivative for high-yield protein ... Cells are derived from a high-yielding clone ... Novagen serum-free TriEx Insect Cell Medium, these ... protein yields by either baculovirus infection or ...
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: